Plain-English translation of NCT06696664 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying why some people with chronic hepatitis B respond well to pegylated interferon-α (a long-acting interferon medication) while others do not. By comparing the genes of patients who were cured with this medication to those who weren't cured, scientists hope to identify genetic markers that predict who will benefit most from this treatment.
Currently, doctors cannot reliably predict which patients will respond well to this medication before starting treatment. By identifying genetic patterns linked to successful outcomes, this medication could be better targeted to patients most likely to benefit, improving treatment results overall.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this study, researchers will collect a blood sample from you once. Your sample will be analyzed using advanced genetic sequencing technology to identify your genetic makeup. The information gathered from comparing your genes with those of other participants will help scientists create a tool to predict treatment outcomes for future patients with hepatitis B.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
China